Janssen Ceases Development of RSV Vaccine for Adults
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Following a safety review, the FDA and the CDC have lifted the recommended pause on the Johnson & Johnson COVID-19 vaccine.
STAT News reported that Johnson & Johnson’s Covid-19 vaccine study has been paused due to an unexplained illness in a study participant.